• Oncolytics Biotech will present its Phase 2 REO 033 trial-in-progress abstract at ESMO 2026, rather than new treatment results.
• The randomized study compares pelareorep with standard chemotherapy and bevacizumab against standard treatment alone in previously treated RAS-mutant, microsatellite-stable metastatic colorectal cancer.
• Enrollment targets 30 patients per arm to validate earlier findings suggesting improved tumor response and survival compared with historical treatment outcomes.
• Recent FDA interactions opened a path to a pivotal expansion that could support accelerated approval, with full approval dependent on progression-free survival.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200935PRIMZONEFULLFEED9849200) on October 20, 2026, and is solely responsible for the information contained therein.